Figure 1

Candidate genes and pathways modulated in normal mammary epithelium by rexinoid bexarotene in three different transgenic mice mammary cell models were identified through a three-stage process: A. Identification of differentially expressed genes in mammary gland as a result of treatment with bexarotene comparing with vehicle control, in each of the mammary cancer models B. Inter-model comparison for the identification of overlapping gene expression profiles. C. Identification of associated functional modules and pathways affected by bexarotene treatment.